FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996231878> ?p ?o ?g. }

• W2996231878 endingPage "318" @default.
• W2996231878 startingPage "305" @default.
• W2996231878 abstract "Basal-bolus (BB) regimens are generally used to intensify basal insulin therapy in patients with type 2 diabetes (T2D) not meeting glycemic targets. However, drawbacks include multiple injection burden and risk of weight gain and hypoglycemia. A once-daily titratable fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) may provide a simple, well-tolerated, and efficacious alternative. We compared these treatments in a post hoc propensity score matched analysis using randomized trial data.From the LixiLan-L study, 195 patients who had been randomized to iGlarLixi were matched for age, sex, race, T2D duration, baseline body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose, insulin dose, and metformin use to 195 patients who had been randomized to a BB regimen in the GetGoal Duo-2 trial.At study end, estimated treatment differences for reduction in HbA1c and weight change, and ratio of hypoglycemia events per patient-year (BB vs iGlarLixi) were - 0.28% (standard error 0.08, P = 0.0002), - 1.32 kg (standard error 0.30, P < 0.0001), and 2.85 (P < 0.0001), respectively, all favoring iGlarLixi over BB. Also, proportions of patients reaching individual and composite goals (HbA1c < 7% [< 53 mmol/mol], no weight gain, and no hypoglycemia) were higher in the iGlarLixi compared with the BB treatment group. Gastrointestinal side effects were more common with iGlarLixi.In patients with T2D inadequately controlled on basal insulin, iGlarLixi offers an effective alternative to BB regimen for reducing HbA1c, without increased risk of hypoglycemia and weight gain.ClinicalTrials.gov: NCT02058160 (LixiLan-L trial); NCT01768559 (GetGoal Duo-2 trial). Plain language summary available for this article." @default.
• W2996231878 created "2019-12-26" @default.
• W2996231878 creator A5002832666 @default.
• W2996231878 creator A5013052910 @default.
• W2996231878 creator A5014462281 @default.
• W2996231878 creator A5040652845 @default.
• W2996231878 creator A5046602426 @default.
• W2996231878 creator A5056611427 @default.
• W2996231878 creator A5061677162 @default.
• W2996231878 creator A5066279531 @default.
• W2996231878 creator A5076844452 @default.
• W2996231878 date "2019-12-17" @default.
• W2996231878 modified "2023-10-16" @default.
• W2996231878 title "Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis" @default.
• W2996231878 cites W2002757015 @default.
• W2996231878 cites W2106758571 @default.
• W2996231878 cites W2147743786 @default.
• W2996231878 cites W2149194615 @default.
• W2996231878 cites W2162409127 @default.
• W2996231878 cites W2162523308 @default.
• W2996231878 cites W2167914620 @default.
• W2996231878 cites W2256432642 @default.
• W2996231878 cites W2307033456 @default.
• W2996231878 cites W2397268769 @default.
• W2996231878 cites W2404273804 @default.
• W2996231878 cites W2514766623 @default.
• W2996231878 cites W2517165909 @default.
• W2996231878 cites W2521422828 @default.
• W2996231878 cites W2601745204 @default.
• W2996231878 cites W2739009446 @default.
• W2996231878 cites W2792254305 @default.
• W2996231878 cites W2799736340 @default.
• W2996231878 cites W2842474032 @default.
• W2996231878 cites W4247704066 @default.
• W2996231878 doi "https://doi.org/10.1007/s13300-019-00735-7" @default.
• W2996231878 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6965545" @default.
• W2996231878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31848983" @default.
• W2996231878 hasPublicationYear "2019" @default.
• W2996231878 type Work @default.
• W2996231878 sameAs 2996231878 @default.
• W2996231878 citedByCount "16" @default.
• W2996231878 countsByYear W29962318782020 @default.
• W2996231878 countsByYear W29962318782021 @default.
• W2996231878 countsByYear W29962318782022 @default.
• W2996231878 countsByYear W29962318782023 @default.
• W2996231878 crossrefType "journal-article" @default.
• W2996231878 hasAuthorship W2996231878A5002832666 @default.
• W2996231878 hasAuthorship W2996231878A5013052910 @default.
• W2996231878 hasAuthorship W2996231878A5014462281 @default.
• W2996231878 hasAuthorship W2996231878A5040652845 @default.
• W2996231878 hasAuthorship W2996231878A5046602426 @default.
• W2996231878 hasAuthorship W2996231878A5056611427 @default.
• W2996231878 hasAuthorship W2996231878A5061677162 @default.
• W2996231878 hasAuthorship W2996231878A5066279531 @default.
• W2996231878 hasAuthorship W2996231878A5076844452 @default.
• W2996231878 hasBestOaLocation W29962318781 @default.
• W2996231878 hasConcept C126322002 @default.
• W2996231878 hasConcept C134018914 @default.
• W2996231878 hasConcept C168563851 @default.
• W2996231878 hasConcept C2776442814 @default.
• W2996231878 hasConcept C2777180221 @default.
• W2996231878 hasConcept C2777538456 @default.
• W2996231878 hasConcept C2779306644 @default.
• W2996231878 hasConcept C2779920387 @default.
• W2996231878 hasConcept C2780323712 @default.
• W2996231878 hasConcept C2780473172 @default.
• W2996231878 hasConcept C2780668416 @default.
• W2996231878 hasConcept C2781413609 @default.
• W2996231878 hasConcept C2909524832 @default.
• W2996231878 hasConcept C555293320 @default.
• W2996231878 hasConcept C71924100 @default.
• W2996231878 hasConceptScore W2996231878C126322002 @default.
• W2996231878 hasConceptScore W2996231878C134018914 @default.
• W2996231878 hasConceptScore W2996231878C168563851 @default.
• W2996231878 hasConceptScore W2996231878C2776442814 @default.
• W2996231878 hasConceptScore W2996231878C2777180221 @default.
• W2996231878 hasConceptScore W2996231878C2777538456 @default.
• W2996231878 hasConceptScore W2996231878C2779306644 @default.
• W2996231878 hasConceptScore W2996231878C2779920387 @default.
• W2996231878 hasConceptScore W2996231878C2780323712 @default.
• W2996231878 hasConceptScore W2996231878C2780473172 @default.
• W2996231878 hasConceptScore W2996231878C2780668416 @default.
• W2996231878 hasConceptScore W2996231878C2781413609 @default.
• W2996231878 hasConceptScore W2996231878C2909524832 @default.
• W2996231878 hasConceptScore W2996231878C555293320 @default.
• W2996231878 hasConceptScore W2996231878C71924100 @default.
• W2996231878 hasFunder F4320307781 @default.
• W2996231878 hasIssue "1" @default.
• W2996231878 hasLocation W29962318781 @default.
• W2996231878 hasLocation W29962318782 @default.
• W2996231878 hasLocation W29962318783 @default.
• W2996231878 hasLocation W29962318784 @default.
• W2996231878 hasLocation W29962318785 @default.
• W2996231878 hasLocation W29962318786 @default.
• W2996231878 hasLocation W29962318787 @default.
• W2996231878 hasOpenAccess W2996231878 @default.
• W2996231878 hasPrimaryLocation W29962318781 @default.
• W2996231878 hasRelatedWork W1554389371 @default.

• next